Please login to the form below

Not currently logged in
Email:
Password:

Chlamydia test approved for use in EU

A new test for chlamydia, produced by pharmaceutical company Roche, has received CE Mark certification, allowing it to be sold in the EU for clinical use
A new test for chlamydia, produced by pharmaceutical company Roche, has received CE Mark certification, allowing it to be sold in the EU for clinical use.

Chlamydia trachomatis is the most commonly diagnosed STI in England, with approximately two-thirds of cases affecting younger age groups. The infection often has no obvious symptoms and left undetected it will not only continue to be spread through the community, but can also lead to complications such as pelvic inflammatory disease or infertility in women.

"Unexpected mutations in the DNA of an infectious agent such as chlamydia can disrupt laboratory testing and, by extension, proper treatment of patients," said Dr Teresa L. Wright, OBE, chief medical officer at Roche Molecular Diagnostics.

This test, known as COBAS TaqMan CT Test v2.0, differs from other tests as it uses a dual target approach helping to ensure reliability even when mutations occur within the bacteria's DNA.

Using specifically designed analysis equipment, results can be obtained just two and a half hours after a sample is prepared.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics